Pharmabiz13m
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...
Tribune Chronicle36m
Commissioners look at homes for EMA, coroner, 911 center
WARREN — Trumbull County commissioners believe they are close to addressing concerns about the Trumbull County 911 Center, Emergency ...
GlobalData on MSN18h
EMA to review GSK’s Nucala for COPD treatment expansion
GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...
Zacks Investment Research on MSN1d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...
European regulators to review GSK's asthma drug Nucala to treat COPD
The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
European Medicines Agency: Interactive map provides information on studies
The European Medicines Agency provides an interactive map with data from the information system for clinical trials. This is ...
Pharmabiz18h
CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer
CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer: Suzhou, China Tuesday, March 25, 2025, 17:00 Hrs [IST] C ...